Extracellular Y RNA fragments could become a new test case for macrophage control in GI cancer
Tumor-derived extracellular vesicles are already recognized as active messengers, but assigning a single biological effect to one RNA cargo remains difficult. In gastrointestinal cancer, the question is not whether vesicles reach immune cells; it is whether a defined Y RNA fragment actually enters the right intracellular compartment, binds the right protein, and changes macrophage behavior in a measurable way. The review separates those steps instead of collapsing them into a single assumption.
That separation matters because macrophages can respond to many things at once: RNA cargoes, proteins, lipids, and soluble tumor products. A vesicle preparation that contains a Y RNA fragment does not prove the fragment caused the immune phenotype. A response observed in recipient macrophages can reflect uptake without delivery, endosomal sensing instead of cytosolic action, or even the influence of other vesicle contents.
The authors place YBX1 at the center of a proposed mechanism, but only as a hypothesis that still needs direct proof in gastrointestinal cancer. Separate experimental systems link YBX1 methylation to fragment sorting, methylated Y3 RNA to YBX1 binding and PARP1 activity, and extracellular hY4 to monocyte responses through TLR7. Those are related observations, not a continuous pathway.
Why Y RNAs are biologically plausible but still unproven messengers
Human Y RNAs are short, structured Pol III transcripts that bind RO60. In normal physiology, that complex participates in RNA quality control, and under stress or apoptosis Y RNAs can be cleaved into distinct fragments. Their biology already suggests they are not random debris. They can be processed, packaged, and released in ways that make them credible candidates for intercellular signaling.
Yet Y RNA fragmentation differs from canonical microRNA production. In one HCT116 knockout system, most tRNA-, Y RNA-, and rRNA-derived small-RNA signals did not fall after loss of DROSHA, DGCR8, XPO5, or DICER. Another study found structural requirements for RNY5 cleavage, with RO60 and RNase L contributing in some settings. These findings support a noncanonical origin, but they do not authorize a universal rule for every tissue or tumor model.
The methylation question is even more unsettled. In one radiation-related study, synthetic Y3-derived fragments showed NSUN2-dependent m5C modification in complementary assays, with YBX1 and PARP1 implicated in repair-related biology. Separate mRNA work connects NSUN2 and YBX1 in transcript stability, and a bladder-cancer study identified a YBX1 residue important for m5C recognition. None of those data establish what happens to a naturally transferred Y RNA fragment in a gastrointestinal tumor macrophage.
A short RNA is only useful as a messenger if it survives export, arrives intact, and reaches a compartment where it can act.
Gastrointestinal cancer studies support macrophage reprogramming, not a Y RNA-specific mechanism
The GI cancer literature already contains multiple examples of extracellular vesicle-associated macrophage effects. In colorectal cancer, miR-934 was linked to PTEN/PI3K-AKT signaling, M2-polarization readouts, and CXCL13-associated liver metastasis. In pancreatic cancer, hypoxic tumor vesicles enriched in miR-301a-3p were tied to PTEN/PI3K-gamma signaling and macrophage polarization. Hepatocellular carcinoma studies reported vesicle-associated miR-23a-3p effects on macrophage PD-L1 and CD8-positive T-cell activity, as well as miR-21-5p linked to RhoB-associated polarization.
These studies prove the concept that tumor vesicles can alter macrophages. They do not prove that Y RNAs do so through the same route. The review repeatedly returns to a narrow point: RNA detection is not the same as functional delivery, and functional delivery is not the same as mechanism.
The mutant-p53 colorectal cancer study built around miR-1246 is a useful cautionary example because the sequence commonly called miR-1246 overlaps a fragment of RNU2-1, the U2 small nuclear RNA. Macrophages also contain endogenous U2 RNA, so increased signal in exposed cells cannot by itself distinguish donor transfer from endogenous background. Full fragment boundaries, orthogonal size-resolved assays, donor-specific tracing, and sequence-specific loss-and-rescue experiments are required before a transfer claim becomes convincing.
YBX1 offers a mechanistic bridge, but the bridge has not been crossed in GI macrophages
The proposed model in this review is straightforward: a sequence-defined Y RNA fragment could be packaged by a donor tumor cell, transferred by extracellular vesicle, bound by YBX1 in a methylation-sensitive manner, and then alter a molecular process inside the recipient macrophage before changing cell behavior. Each step is testable. Each step is also vulnerable to a different failure mode.
EV loading is one of the most uncertain steps. EV RNA profiles can differ from donor-cell RNA profiles, and a proteo-transcriptomic study reported co-enrichment of RNY3 and YBX1. A different lung cancer study showed YBX1-methylation-dependent export of an hY4-derived fragment. Still, those results do not prove the same process operates in GI cancer, and they do not prove the same fragment is responsible across disease settings.
Uptake is not delivery, and delivery is not function
This distinction is central to the entire review. EV interaction with recipient cells does not automatically mean efficient RNA transfer, and recipient-cell uptake does not guarantee access to the compartment where the RNA could act. Experimental work with EVs has shown that functional miRNA transfer can be inefficient in some systems, which is why cargo copy number, exposure dose, membrane association, and intracellular localization all need direct measurement.
The review also keeps open alternative explanations. Endosomal RNA sensing could explain a macrophage response without any cytosolic YBX1 interaction. Other vesicle cargoes could drive the phenotype. Donor-cell changes could alter the vesicle proteome or lipid content in parallel with RNA packaging. A reader looking for a single elegant pathway will not find one here, because the biology does not justify one yet.
Non-GI examples show what is possible, not what is established in cancer
Outside GI cancer, Y RNA fragments have already been linked to myeloid biology. In chronic lymphocytic leukemia, hY4 was tied to cytokine release and PD-L1 expression through TLR7, and another study described hY4-associated CCL24 expression and nurse-like differentiation in monocytes. Those findings support the idea that Y RNAs can matter in immune cells. They do not establish m5C-sensitive recognition by recipient-cell YBX1.
A synthetic YF1 fragment from cardiosphere-derived vesicles is also informative. In a hypertrophic cardiomyopathy model, systemic administration reduced inflammatory monocyte mobilization and macrophage accumulation. Because the intervention used the synthetic RNA directly, it does not prove native vesicle-mediated delivery. It does, however, show that a short Y RNA fragment can have immune effects in vivo when the delivery route is controlled.
The review also references a cardiac study in which a synthetic Y RNA fragment reduced inflammatory-cell recruitment, reinforcing the point that RNA responses differ by disease context and treatment design. A fragment with one biological effect in one setting may behave differently in a tumor microenvironment saturated with inflammatory and suppressive cues.
What would settle the question in gastrointestinal cancer
The cleanest path forward is experimental, not conceptual. A GI cancer model would need to demonstrate functional delivery of a defined Y RNA fragment, sequence-resolved evidence of recipient-cell entry, YBX1-dependent binding, and a downstream macrophage phenotype in the same system. Without those steps, the hypothesis remains plausible but unconfirmed.
The unresolved issues are precise. Does RNA methylation occur before export or after transfer? Does the fragment bind YBX1 in recipient macrophages, or does another sensor dominate the response? Does the final immune effect support tumor growth, restrain it, or vary by tumor context? Those questions are not semantic; they determine whether Y RNA biology becomes a mechanistic explanation or stays a descriptive observation in extracellular vesicle research.